CEP-701 for PH-negative Myelofibrosis
Phase 2
Completed
- Conditions
- MyelofibrosisLeukemia
- Interventions
- Drug: CEP-701
- First Posted Date
- 2007-06-29
- Last Posted Date
- 2012-06-25
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 27
- Registration Number
- NCT00494585
- Locations
- 🇺🇸
The University of Texas M.D. Anderson Cancer Center, Houston, Texas, United States
Ibritumomab Tiuxetan for Treatment of Non-Follicular CD20+ Indolent Lymphomas
Phase 2
Terminated
- Conditions
- Lymphoma
- Interventions
- First Posted Date
- 2007-06-28
- Last Posted Date
- 2013-05-31
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 6
- Registration Number
- NCT00493454
- Locations
- 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States
Delirium Recall in Advanced Cancer Patients
Completed
- Conditions
- Advanced CancerDelirium
- Interventions
- Behavioral: Questionnaire
- First Posted Date
- 2007-06-28
- Last Posted Date
- 2012-07-30
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 200
- Registration Number
- NCT00493714
- Locations
- 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States
Prospective Validation Trial of Circulating Tumor Cells (CTCs) in Women With Metastatic Breast Cancer
Completed
- Conditions
- Breast Cancer
- Interventions
- Procedure: Blood Sample
- First Posted Date
- 2007-06-28
- Last Posted Date
- 2012-07-31
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 660
- Registration Number
- NCT00493350
- Locations
- 🇺🇸
U.T.M.D. Anderson Cancer Center, Houston, Texas, United States
Interleukin 11, Thrombocytopenia, Imatinib in Chronic Myelogenous Leukemia (CML) Patients
Phase 2
Completed
- Conditions
- LeukemiaChronic Myelogenous LeukemiaChronic Myeloid Leukemia
- Interventions
- First Posted Date
- 2007-06-28
- Last Posted Date
- 2012-02-20
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 8
- Registration Number
- NCT00493181
- Locations
- 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States
Ontak (Denileukin Diftitox) in Patients With Systemic Mastocytosis (SM)
Phase 2
Completed
- Conditions
- LeukemiaSystemic Mastocytosis
- Interventions
- Drug: Ontak (Denileukin Diftitox)
- First Posted Date
- 2007-06-28
- Last Posted Date
- 2012-02-08
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 8
- Registration Number
- NCT00493129
- Locations
- 🇺🇸
The University of Texas M.D. Anderson Cancer Center, Houston, Texas, United States
Zevalin (Ibritumomab Tiuxetan) for Early Stage Indolent Lymphomas
- First Posted Date
- 2007-06-28
- Last Posted Date
- 2022-09-15
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 31
- Registration Number
- NCT00493467
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
A Study to Determine Whether Perioperative Energy Dynamics Correlates With Postoperative Outcomes
Recruiting
- Conditions
- Pelvic CancerAbdominal Cancer
- Interventions
- Other: Cardiopulmonary Exercise Testing (CPET)
- First Posted Date
- 2007-06-28
- Last Posted Date
- 2024-05-23
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 200
- Registration Number
- NCT00493688
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Phase I Study of Gimatecan in Patients With Myelodysplastic Syndromes
- First Posted Date
- 2007-06-28
- Last Posted Date
- 2015-05-13
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 16
- Registration Number
- NCT00493571
- Locations
- 🇺🇸
The University of Texas M.D. Anderson Cancer Center, Houston, Texas, United States
Aerosol L9-NC and Temozolomide in Ewing's Sarcoma
- First Posted Date
- 2007-06-27
- Last Posted Date
- 2012-08-02
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 10
- Registration Number
- NCT00492141
- Locations
- 🇺🇸
U.T.M.D. Anderson Cancer Center, Houston, Texas, United States
© Copyright 2025. All Rights Reserved by MedPath